Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07810062
PHASE2

A Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV- Negative Women

Sponsor: Centre for Infectious Disease Research in Zambia

View on ClinicalTrials.gov

Summary

A double blinded, Randomized, Placebo- controlled phase II trial to assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV- negative women

Official title: A Double-blinded, Randomized, Placebo-controlled Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV Negative Women

Key Details

Gender

FEMALE

Age Range

18 Years - 30 Years

Study Type

INTERVENTIONAL

Enrollment

990

Start Date

2023-08-28

Completion Date

2025-06-30

Last Updated

2026-09-09

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Broad band monoclonal antibodies named as CAP256V2LS and VRC07- 523LS

HIV prevention

Locations (1)

Matero Clinical Research Site

Lusaka, Lusaka Province, Zambia